A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Latest Information Update: 24 Dec 2021
At a glance
- Drugs Opicinumab (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Proof of concept; Therapeutic Use
- Acronyms SYNERGY
- Sponsors Biogen
- 12 Oct 2018 Results assessing biomarkers of remyelination and patient stratification for opicinumab treatment effect, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 28 Oct 2017 Results of a post-hoc analysis studying demographic and baseline predictors of opicinumab treatment response, and identifying a subpopulation with a greater treatment response presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
- 18 Oct 2017 Data from this trial will be presented at the ECTRIMS-ACTRIMS 2017 meeting, according to a Biogen media release.